Meibomian gland dysfunction (MGD) is a term used to describe a group of disorders, both congenital and acquired. Disruption of meibomian gland function negatively impacts both the quality and quantity of meibum secreted, which in turn affects ocular surface health through changes in tear film composition. Increased tear evaporation, hyperosmolarity, inflammation, and ocular surface damage can subsequently occur and cause discomfort, visual disruption, and sensation of dry eyes.
Market Dynamics
There are various late-stage pipeline drugs for dry eye associated meibomian gland dysfunction syndrome treatment such as RegeneRx’s RGN-259, which is expected to be the strongest pipeline asset for the meibomian gland dysfunction syndrome treatment market. For instance, in April 2018, RegeneRx Biopharmaceuticals, inc. announced the outcome of discussions between its U.S. joint venture, ReGenTree LLC, and the FDA regarding the results of the completed phase 3 clinical trial (ARISE-2) and the future development requirements for a New Drug Application (NDA) submission of RGN-259, a novel drug candidate to treat dry eye syndrome associated meibomian gland dysfunction syndrome.
Key features of the study:
This report provides in-depth analysis of the U.S. meibomian gland dysfunction market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2030), considering 2019 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the U.S. meibomian gland dysfunction market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Pfizer, inc., AbbVie Inc., Johnson and Johnson Vision Care Inc., Bausch Health Companies Inc., Novartis AG, Santen Pharmaceutical Co., Ltd., I-MED Pharma Inc., OASIS Medical, Sentiss Pharma Pvt. Ltd., RegeneRx, and Akorn, inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The U.S. meibomian gland dysfunction market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. meibomian gland dysfunction market
Detailed Segmentation:
U.S. Meibomian Gland Dysfunction Market, By Drug Type:
Cyclosporine
Omega-3 supplements
Antibacterial Eye Drops
Steroids
AZR MD 001
TP 03
NOV03 (Novatears)
HY02 – Minocycline
U.S. Meibomian Gland Dysfunction Market, By Route of Administration:
Oral
Topical
U.S. Meibomian Gland Dysfunction Market, By Distribution Channel:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.
What we provide:
Contact Us:
Mr. Shah
Coherent Market Insights Pvt Ltd, 1001 4th Ave, #3200 Seattle, WA 98154, U.S.
sales@coherentmarketinsights.com
Like it? Share it!
About the Author
Trupti Joined: March 17th, 2021 Articles Posted: 36
